Literature DB >> 19636218

Lack of consistent association of thyrotropin receptor mutations in vitro activity with the clinical course of patients with sporadic non-autoimmune hyperthyroidism.

J Lueblinghoff1, S Mueller, J Sontheimer, R Paschke.   

Abstract

BACKGROUND: Up to date, 14 patients with sporadic non-autoimmune hyperthyroidism (SNAH) caused by sporadic germline mutations in the TSH receptor (TSHR) gene have been reported. Despite considerable differences in the activity of hyperthyroidism, all SNAH case reports concluded that the demonstrated constitutive activity explains the phenotype. AIM: Recently, linear regression analysis (LRA) of constitutive activity as a function of TSHR expression determined by 125I-bTSH binding or fluorescence activated cell sorting analysis was described as a more reliable way of characterizing the in vitro activity (IVA) of a constitutively activating TSHR mutation. Therefore, we analyzed a possible genotype-phenotype correlation in a systematic review of the case reports and investigated the TSHR mutation's LRA in selected cases.
MATERIAL AND METHODS: We determined the LRA for all sporadic germline mutations which had not previously been reported. Moreover, we systematically evaluated all case reports of SNAH for evidence of an association of the clinical course (CC) with the IVA of the mutated TSHR.
RESULTS: The LRA determined were: M453T (5.2+/-0.8), L512Q (4.5+/-0.7), I568T (25.6+/-6.3), F631L (45.9+/-9.4), T632I (14.5+/-2.7), D633Y (16.4+/-6.4). None of the 10 examined clinical signs showed a significant association with the LRA. Moreover, the comparison of the CC of patients harboring the same mutation (S281N, M453T, I568T, S505N) also showed no relation of the clinical activity with a high LRA.
CONCLUSION: Considering the different diagnostic circumstances, therapeutic strategies and the limitations of a systematic analysis of case reports due to the restricted number of case reports and limited follow-up we found no consistent relation of the TSHR mutation's IVA determined by LRA with the CC of patients with SNAH. This may also be due to the action of genetic, epigenetic, and environmental modifiers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636218     DOI: 10.1007/BF03345784

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

1.  Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis.

Authors:  B Trülzsch; K Krohn; P Wonerow; S Chey; H P Holzapfel; F Ackermann; D Führer; R Paschke
Journal:  J Mol Med (Berl)       Date:  2001       Impact factor: 4.599

2.  Preferences of transmembrane helices for cooperative amplification of G(alpha)s and G (alpha)q signaling of the thyrotropin receptor.

Authors:  H Jaeschke; G Kleinau; J Sontheimer; S Mueller; G Krause; R Paschke
Journal:  Cell Mol Life Sci       Date:  2008-12       Impact factor: 9.261

3.  An aromatic environment in the vicinity of serine 281 is a structural requirement for thyrotropin receptor function.

Authors:  H Jaeschke; S Neumann; G Kleinau; S Mueller; M Claus; G Krause; R Paschke
Journal:  Endocrinology       Date:  2006-01-12       Impact factor: 4.736

4.  Long-term follow-Up of an infant with thyrotoxicosis due to germline mutation of the TSH receptor gene (Met453Thr).

Authors:  L Lavard; A Sehested; B Brock Jacobsen; J Muller; H Perrild; U Feldt-Rasmussen; J Parma; G Vassart
Journal:  Horm Res       Date:  1999

5.  Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene.

Authors:  M Tonacchera; P Agretti; V Rosellini; G Ceccarini; A Perri; M Zampolli; R Longhi; D Larizza; A Pinchera; P Vitti; L Chiovato
Journal:  Thyroid       Date:  2000-10       Impact factor: 6.568

6.  Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans.

Authors:  Supriya Srinivasan; Cecile Lubrano-Berthelier; Cedric Govaerts; Franck Picard; Pamela Santiago; Bruce R Conklin; Christian Vaisse
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

7.  A family with a novel TSH receptor activating germline mutation (p.Ala485Val).

Authors:  Sema Akcurin; Doga Turkkahraman; Carolyn Tysoe; Sian Ellard; Anne De Leener; Gilbert Vassart; Sabine Costagliola
Journal:  Eur J Pediatr       Date:  2008-01-04       Impact factor: 3.183

8.  A novel TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism.

Authors:  Zheng Liu; Yuanming Sun; Qingming Dong; Mingliang He; Christopher H K Cheng; Feiyue Fan
Journal:  J Hum Genet       Date:  2008-02-29       Impact factor: 3.172

Review 9.  Persistent neonatal thyrotoxicosis in a neonate secondary to a rare thyroid-stimulating hormone receptor activating mutation: case report and literature review.

Authors:  Mark G Watkins; Prapai Dejkhamron; Jeffrey Huo; Delia M Vazquez; Ram K Menon
Journal:  Endocr Pract       Date:  2008 May-Jun       Impact factor: 3.443

Review 10.  Iodine deficiency in Europe and its consequences: an update.

Authors:  François Delange
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-06-01       Impact factor: 9.236

View more
  8 in total

1.  Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutation with weakly increased constitutive activity.

Authors:  Eijun Nishihara; Chun-Rong Chen; Takuya Higashiyama; Yumiko Mizutori-Sasai; Mitsuru Ito; Sumihisa Kubota; Nobuyuki Amino; Akira Miyauchi; Basil Rapoport
Journal:  Thyroid       Date:  2010-10-07       Impact factor: 6.568

2.  Novel germline mutation (Leu512Met) in the thyrotropin receptor gene (TSHR) leading to sporadic non-autoimmune hyperthyroidism.

Authors:  Stephanie A Roberts; Jennifer E Moon; Andrew Dauber; Jessica R Smith
Journal:  J Pediatr Endocrinol Metab       Date:  2017-03-01       Impact factor: 1.634

3.  Sporadic congenital nonautoimmune hyperthyroidism caused by P639S mutation in thyrotropin receptor gene.

Authors:  Patrizia Agretti; Giuseppina De Marco; Martina Biagioni; Antonio Iannilli; Marco Marigliano; Aldo Pinchera; Paolo Vitti; Valentino Cherubini; Massimo Tonacchera
Journal:  Eur J Pediatr       Date:  2012-02-28       Impact factor: 3.183

4.  2012 European thyroid association guidelines for the management of familial and persistent sporadic non-autoimmune hyperthyroidism caused by thyroid-stimulating hormone receptor germline mutations.

Authors:  R Paschke; M Niedziela; B Vaidya; L Persani; B Rapoport; J Leclere
Journal:  Eur Thyroid J       Date:  2012-10-04

5.  Severe thyrotoxicosis in an infant revealing familial nonautoimmune hyperthyroidism with a novel (C672W) stimulating thyrotropin receptor germline mutation.

Authors:  Isabelle Oliver-Petit; Frédérique Savagner; Solange Grunenwald; Magaly Vialon; Thomas Edouard; Philippe Caron
Journal:  Clin Case Rep       Date:  2017-10-25

6.  Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies.

Authors:  Haixia Guan; Danielle Matonis; Gianluca Toraldo; Stephanie L Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-25       Impact factor: 5.555

7.  Central TSH Dysregulation in a Patient with Familial Non-Autoimmune Autosomal Dominant Hyperthyroidism Due to a Novel Thyroid-Stimulating Hormone Receptor Disease-Causing Variant.

Authors:  Jasna Suput Omladic; Maja Pajek; Urh Groselj; Katarina Trebusak Podkrajsek; Magdalena Avbelj Stefanija; Mojca Zerjav Tansek; Primoz Kotnik; Tadej Battelino; Darja Smigoc Schweiger
Journal:  Medicina (Kaunas)       Date:  2021-02-25       Impact factor: 2.430

8.  Familial Non-autoimmune Hyperthyroidism in Family Members Across Four Generations Due To a Novel Disease-causing Variant in The Thyrotropin Receptor Gene.

Authors:  A Malej; M Avbelj Stefanija; N Bratanič; K Trebušak Podkrajšek
Journal:  Balkan J Med Genet       Date:  2021-03-23       Impact factor: 0.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.